159 related articles for article (PubMed ID: 26274882)
1. Sofosbuvir (Sovaldi) for hepatitis C virus.
Lomberk M; Klibanov OM
Nurse Pract; 2015 Sep; 40(9):16-9. PubMed ID: 26274882
[No Abstract] [Full Text] [Related]
2. Pharmaceuticals. Advocates protest the cost of a hepatitis C cure.
Cohen J
Science; 2013 Dec; 342(6164):1302-3. PubMed ID: 24337268
[No Abstract] [Full Text] [Related]
3. New Indications for Harvoni.
Med Lett Drugs Ther; 2016 Jan; 58(1485):6. PubMed ID: 27099890
[No Abstract] [Full Text] [Related]
4. A combination of ledipasvir and sofosbuvir (Harvoni) for hepatitis C.
Med Lett Drugs Ther; 2014 Nov; 56(1455):111-2. PubMed ID: 25372848
[No Abstract] [Full Text] [Related]
5. Harvoni (ledipasvir and sofosbuvir) for hepatitis C.
Mullins C; Gibson W; Klibanov OM
Nurse Pract; 2015 Nov; 40(11):22-6. PubMed ID: 26474199
[No Abstract] [Full Text] [Related]
6. Sofosbuvir for the treatment of hepatitis C virus infection.
Rolland S; Vachon ML
CMAJ; 2015 Feb; 187(3):203-204. PubMed ID: 25002563
[No Abstract] [Full Text] [Related]
7. Building bridges and providing transparency to the hepatitis C virus drug approval process.
Ghany MG; Liang TJ
Gastroenterology; 2014 Dec; 147(6):1201-3. PubMed ID: 25449025
[No Abstract] [Full Text] [Related]
8. Sovaldi dilemma likely to get worse.
Carroll J
Manag Care; 2014 Sep; 23(9):9, 12. PubMed ID: 25282860
[No Abstract] [Full Text] [Related]
9. New drugs: simeprevir, sofosbuvir, and dolutegravir sodium.
Hussar DA; Jin ZJ
J Am Pharm Assoc (2003); 2014; 54(2):202-7. PubMed ID: 24632934
[No Abstract] [Full Text] [Related]
10. Mutant Ninja viruses.
Foster GR
Hepatology; 2015 Feb; 61(2):421-3. PubMed ID: 25266372
[No Abstract] [Full Text] [Related]
11. New concepts of sofosbuvir-based treatment regimens in patients with hepatitis C.
Mariño Z; van Bömmel F; Forns X; Berg T
Gut; 2014 Feb; 63(2):207-15. PubMed ID: 24253934
[No Abstract] [Full Text] [Related]
12. Trials wrap on interferon-free hepatitis C regimen.
Dalzell MD
Manag Care; 2013 Apr; 22(4):41-2. PubMed ID: 23678562
[No Abstract] [Full Text] [Related]
13. Guideline: New HCV drugs should go to sickest patients.
Kuehn BM
JAMA; 2014 Sep; 312(11):1084-5. PubMed ID: 25226461
[No Abstract] [Full Text] [Related]
14. Quantum leaps, microeconomics, and the treatment of patients with hepatitis C and HIV coinfection.
Saag MS
JAMA; 2014 Jul 23-30; 312(4):347-8. PubMed ID: 25038351
[No Abstract] [Full Text] [Related]
15. Dare to refuse the exorbitant price of Sovaldi!
Prescrire Int; 2014 Nov; 23(154):278. PubMed ID: 25954802
[No Abstract] [Full Text] [Related]
16. FDA approvals usher in the post-interferon era in HCV.
Sheridan C
Nat Biotechnol; 2014 Jan; 32(1):3-5. PubMed ID: 24406908
[No Abstract] [Full Text] [Related]
17. Lawsuit seeks access to data from hepatitis C drug trial.
McCarthy M
BMJ; 2015 Jun; 350():h3564. PubMed ID: 26126508
[No Abstract] [Full Text] [Related]
18. Two Antiviral Drugs Approved For Adolescents With HCV.
Aschenbrenner DS
Am J Nurs; 2017 Aug; 117(8):22. PubMed ID: 28749879
[No Abstract] [Full Text] [Related]
19. Sofosbuvir and ribavirin use in wait-listed patients with hepatitis C should be selective.
Price JC; Terrault NA
Liver Int; 2015 Jan; 35(1):7-8. PubMed ID: 25183500
[No Abstract] [Full Text] [Related]
20. Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.
Curry MP; Forns X; Chung RT; Terrault NA; Brown R; Fenkel JM; Gordon F; O'Leary J; Kuo A; Schiano T; Everson G; Schiff E; Befeler A; Gane E; Saab S; McHutchison JG; Subramanian GM; Symonds WT; Denning J; McNair L; Arterburn S; Svarovskaia E; Moonka D; Afdhal N
Gastroenterology; 2015 Jan; 148(1):100-107.e1. PubMed ID: 25261839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
